Shinpoong Pharmaceutical Co.,Ltd

KOSE:A019170 Stock Report

Market Cap: ₩529.5b

Shinpoong PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 6/6

Shinpoong PharmaceuticalLtd has a total shareholder equity of ₩268.2B and total debt of ₩41.5B, which brings its debt-to-equity ratio to 15.5%. Its total assets and total liabilities are ₩337.5B and ₩69.3B respectively.

Key information

15.5%

Debt to equity ratio

₩41.50b

Debt

Interest coverage ration/a
Cash₩62.05b
Equity₩268.17b
Total liabilities₩69.31b
Total assets₩337.48b

Recent financial health updates

Recent updates

Does Shinpoong PharmaceuticalLtd (KRX:019170) Have A Healthy Balance Sheet?

Nov 13
Does Shinpoong PharmaceuticalLtd (KRX:019170) Have A Healthy Balance Sheet?

Shinpoong Pharmaceutical Co.,Ltd's (KRX:019170) 30% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sep 11
Shinpoong Pharmaceutical Co.,Ltd's (KRX:019170) 30% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Is Shinpoong PharmaceuticalLtd (KRX:019170) Weighed On By Its Debt Load?

Aug 08
Is Shinpoong PharmaceuticalLtd (KRX:019170) Weighed On By Its Debt Load?

Shinpoong Pharmaceutical Co.,Ltd (KRX:019170) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Apr 24
Shinpoong Pharmaceutical Co.,Ltd (KRX:019170) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Do Shin Poong Pharm.Co.Ltd's (KRX:019170) Earnings Warrant Your Attention?

Mar 07
Do Shin Poong Pharm.Co.Ltd's (KRX:019170) Earnings Warrant Your Attention?

Declining Stock and Decent Financials: Is The Market Wrong About Shin Poong Pharm.Co.,Ltd. (KRX:019170)?

Feb 01
Declining Stock and Decent Financials: Is The Market Wrong About Shin Poong Pharm.Co.,Ltd. (KRX:019170)?

We Wouldn't Rely On Shin Poong Pharm.Co.Ltd's (KRX:019170) Statutory Earnings As A Guide

Jan 05
We Wouldn't Rely On Shin Poong Pharm.Co.Ltd's (KRX:019170) Statutory Earnings As A Guide

Is Shin Poong Pharm.Co.Ltd (KRX:019170) Using Too Much Debt?

Dec 10
Is Shin Poong Pharm.Co.Ltd (KRX:019170) Using Too Much Debt?

Financial Position Analysis

Short Term Liabilities: A019170's short term assets (₩193.8B) exceed its short term liabilities (₩66.4B).

Long Term Liabilities: A019170's short term assets (₩193.8B) exceed its long term liabilities (₩2.9B).


Debt to Equity History and Analysis

Debt Level: A019170 has more cash than its total debt.

Reducing Debt: A019170's debt to equity ratio has reduced from 49.6% to 15.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A019170 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A019170 has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 34.9% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 14:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shinpoong Pharmaceutical Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution